About Entia
Entia is a company based in London (United Kingdom) founded in 2012. Entia has raised $41.29 million across 8 funding rounds from investors including Oxford Technology, BGF and Parkwalk. The company has 28 employees as of March 31, 2021. Entia offers products and services including Liberty. Entia operates in a competitive market with competitors including HORIBA, Quotient Biodiagnostics, Boule Diagnostics, FYR Diagnostics and Mursla, among others.
- Headquarter London, United Kingdom
- Employees 28 as on 31 Mar, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Entia Ltd
- Date of Incorporation 28 Oct, 2014
- Jurisdiction LONDON
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$41.29 M (USD)
in 8 rounds
-
Latest Funding Round
$20.66 M (USD), Series A
Jul 27, 2023
-
Investors
Oxford Technology
& 4 more
-
Employee Count
28
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Entia
Entia offers a comprehensive portfolio of products and services, including Liberty.
At-home solution for blood tests to support cancer care monitoring.
People of Entia
Unlock access to complete
Funding Insights of Entia
Entia has successfully raised a total of $41.29M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $20.66 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Entia
Entia has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Technology, BGF and Parkwalk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Locked | Locked | Locked | |
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage micro-VC investments are focused on UK companies.
|
Locked | Locked | Locked |
Investor details for Entia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Entia
Investment portfolio details for Entia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Entia
Detailed financials for Entia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Entia Comparisons
Peer comparison for Entia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Entia
Entia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HORIBA, Quotient Biodiagnostics, Boule Diagnostics, FYR Diagnostics and Mursla, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Multinational conglomerate
|
|
| Locked | Locked | Locked |
Manufacturer of immunohematology products for use in transfusion diagnostics
|
|
| Locked | Locked | Locked |
Provider of blood count analyzer for human and veterinary applications
|
|
| Locked | Locked | Locked |
In-vitro diagnostic tests for disease detection are provided.
|
|
| Locked | Locked | Locked |
Diagnostic devices for cancer detection are developed using nanostructures.
|
Detailed competitors of Entia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Entia
Complete news archive for Entia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Entia
Entia was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Entia is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Entia is a funded company, having raised a total of $41.29M across 8 funding rounds to date.
As of Mar 31, 2021, the latest employee count at Entia is 28.
Entia was founded in 2012 and is based in London, United Kingdom. Operations focus on the medical diagnostics sector, where point-of-care devices for blood testing are developed. The flagship product, Aptus, utilizes a single drop of blood from capillary, venous, or arterial sources to assess hemoglobin levels and hematocrit. Affinity, another device in development, enables complete blood counts to be performed at the point of care or in home settings.
Entia's top competitors include HORIBA, Quotient Biodiagnostics and Boule Diagnostics.
Entia offers Liberty.
Entia has 5 investors. Key investors include Oxford Technology, BGF, Parkwalk, Innovate UK, and Sussex Place Ventures.
The valuation of Entia is $3.37M as of Aug 2022.